139 studies found for:    Immunodeficiency NOT AIDS | Open Studies
Show Display Options
RSS Create an RSS feed from your search for:
Immunodeficiency NOT AIDS | Open Studies
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Early Diagnosis and Stem Cell Transplantation for Severe Immunodeficiency Diseases
Condition: Severe Immunodeficiency Diseases
Intervention: Drug: Fludarabine, Busulfan, and Anti-Thymocyte Globulin
2 Unknown  Lymphocyte Immunophenotyping in Common Variable Immunodeficiency
Conditions: Common Variable Immunodeficiency;   Granulomatous Disease;   Bronchiectasis;   Immunoglobulin Treatment
Intervention:
3 Recruiting Genetic Basis of Immunodeficiency
Condition: Severe Combined Immunodeficiency
Intervention:
4 Recruiting Pharmacokinetics (PK) and Safety of Subgam®VF in Primary Immunodeficiency Diseases
Conditions: Primary Immune Deficiency Disorders;   Common Variable Immunodeficiency;   X-linked Agammaglobulinaemia;   Hyperimmunoglobulin M Syndrome
Intervention: Biological: Subgam
5 Not yet recruiting Novel Testing Procedures
Condition: Immunodeficiencies
Intervention:
6 Not yet recruiting Neonatal Screening of Severe Combined Immunodeficiencies
Conditions: Severe Combined Immunodeficiency;   Neonatal Screening
Intervention:
7 Not yet recruiting ASIS for GAMMAGARD in Primary Immunodeficiency
Condition: Primary Immunodeficiency
Interventions: Drug: Gadolinium For abdomen;   Drug: Gadolinium For lower back;   Drug: Efficacy of Gammagard subcutaneously at Week 12;   Drug: Efficacy of Gammagard subcutaneously at Week 24;   Drug: Efficacy of Gammagard subcutaneously at Week 36;   Drug: Efficacy of Gammagard subdermally at Week 36;   Drug: Efficacy of Gammagard subdermally at Week 12;   Drug: Efficacy of Gammagard subdermally at Week 24;   Drug: Adverse Reactions of Gammagard subcutaneously at Week 12;   Drug: Adverse Reactions of Gammagard subcutaneously at Week 24;   Drug: Adverse Reactions of Gammagard subcutaneously at Week 36;   Drug: Adverse Reactions of Gammagard subdermally at Week 12;   Drug: Adverse Reactions of Gammagard subdermally at Week 24;   Drug: Adverse Reactions of Gammagard subdermally at Week 36
8 Not yet recruiting Clinical Characteristics and Genetic Profiles of Severe Combined Immunodeficiency in China
Condition: Severe Combined Immunodeficiency
Intervention: Genetic: gene sequencing
9 Recruiting Generalized Neonatal Screening of Severe Combined Immunodeficiencies
Condition: Severe Combined Immunodeficiency, Atypical
Intervention: Biological: SCID screening
10 Recruiting Genetic Basis of Primary Immunodeficiencies
Condition: Immunologic Deficiency Syndrome
Intervention:
11 Recruiting Genetic Study of Immunodeficiency: Search for New Genetic Causes for Primary Immunodeficiencies
Condition: Immunologic Deficiency Syndromes
Interventions: Procedure: blood sampling and skin biopsy;   Procedure: blood sampling or mouth swap;   Procedure: blood sampling
12 Recruiting Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants
Condition: Severe Combined Immunodeficiency Disease, X-linked
Interventions: Genetic: CL20-4i-EF/a-hyc-OPT;   Drug: Busulfan
13 Recruiting Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
Conditions: SCID;   Omenn's Syndrome;   Reticular Dysgenesis;   Wiskott-Aldrich Syndrome;   Bare Lymphocyte Syndrome;   Common Variable Immunodeficiency;   Chronic Granulomatous Disease;   CD40 Ligand Deficiency;   Hyper IgM Syndrome;   X-linked Lymphoproliferative Disease;   Hemophagocytic Lymphohistiocytosis;   Griscelli Syndrome;   Chediak-Higashi Syndrome;   Langerhan's Cell Histiocytosis
Interventions: Drug: Alemtuzumab 0.3 mg;   Drug: Cyclophosphamide;   Drug: Busulfan;   Biological: Stem Cell Transplantation;   Drug: Fludarabine phosphate 40 mg;   Drug: Melphalan;   Drug: Alemtuzumab 0.2 mg;   Drug: Fludarabine phosphate 30 mg;   Drug: MESNA
14 Recruiting Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
Condition: Primary Immunodeficiency
Interventions: Biological: IGIV-C 10%;   Biological: IGSC 20%
15 Recruiting Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting
Condition: Primary Immunodeficiency Disease (PIDD)
Intervention:
16 Recruiting Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1)
Condition: X-linked Severe Combined Immunodeficiency
Intervention: Genetic: Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre
17 Not yet recruiting Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency
Condition: Immunologic Deficiency Syndromes
Intervention: Biological: GC5107
18 Recruiting Investigation of Immune Disorders and Deficiencies
Conditions: Primary Immune Deficiencies;   Autoimmune Diseases;   Inflammatory Diseases;   Common Variable Immune Deficiencies;   Hypogammaglobulinemia
Intervention:
19 Recruiting Diagnostic Immunization With Rabies Vaccine in Patients With PID
Condition: Primary Immunodeficiency
Intervention: Biological: Verorab® (PVRV; Purified Vero Cell Vaccine)
20 Recruiting Immune Regulation in Patients With Common Variable Immunodeficiency and Related Syndromes
Condition: CVID
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years